stella
beta
Safety and Efficacy Study of RXIM002 in Severe, Relapsed or Refractory Autoimmune Diseases — Stella
Recruiting
Back to Relapsed/Refractory B Cell-Mediated Autoimmune Diseases trials
Early Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.
Trial locations
(1 site)
China
Ruijin Hospital, Shanghai, Huangpu District
View full record on ClinicalTrials.gov